Treatment of Meibomian gland disease with the Lipiflow® system: A prospective study

Autor:	Sylvain Michée, Antoine Labbé, Ghislaine Rabut, Christophe Baudouin
Rok vydání:	2013
Předmět:	Osmole medicine.medical_specialty business.industry Meibomian gland General Medicine Ocular rosacea medicine.disease Tear osmolarity eye diseases System a Ophthalmology medicine.anatomical_structure medicine Ocular Surface Disease Index sense organs business Prospective cohort study After treatment
Zdroj:	Acta Ophthalmologica. 91
ISSN:	1755-375X
DOI:	10.1111/j.1755-3768.2013.s010.x
Popis:	Purpose To evaluate the safety and efficacy of Lipiflow® in the treatment of meibomian gland disease (MGD). Methods Twenty eyes of 17 consecutive patients with MGD and evaporative dry eye were included in this study. MGD was associated with ocular rosacea in 58.8% of cases. There were 9 women (52.9%) and 8 men (47.1%) with a mean age of 58.1 ± 16.2 years (28-82 years). Patients underwent a complete ophthalmologic evaluation including two symptoms questionnaires, SPEED® and ocular surface disease index (OSDI), tear film break-up time (TBUT), Schirmer test, meibomian gland evaluation with the Meibomian Gland Evaluator® (MGE), tear film thickness measured with the Lipiview® Ocular Surface Interferometer and tear osmolarity (Tearlab®). Then all eyes were treated with the Lipiflow® system. All patients were evaluated before and one month after treatment. Results According to SPEED questionnaire, symptoms improved significantly one month after treatment (15.4 ± 4.9 vs. 12.7 ± 5.8; p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::56e649e7103fc6de570c3aec4072cd03 https://doi.org/10.1111/j.1755-3768.2013.s010.x Zobrazit plný text záznamu Plný text